«

»

村上 正基

現職:

宮崎大学医学部解剖学講座組織細胞化学分野 客員教授
神奈川歯科大学歯学部病理・組織形態学講座環境病理学 客員教授
特定非営利活動法人領域横断疾患研究機構 理事
学位・資格:
博士(医学),  医師
機構認定皮膚科専門医
厚生省死体解剖資格認定医(病理)
日本医師会認定産業医
厚生労働省認定 臨床研修指導医
略歴:

1990年  聖マリアンナ医科大学医学部卒業
1994年  長崎大学医学部第3解剖学講座 研究生
1995年  藤田保健衛生大学大学院医学系研究科形態系病理学卒業
1995年  藤田保健衛生大学医学部病理学講座 助手
2001年  米国カリフォルニア大学サンディエゴ校皮膚科学 博士研究員
2003年  旭川医科大学病院皮膚科 医員・助手
2007年  北海道社会事業協会富良野病院皮膚科 主任医長・部長
2009年  旭川医科大学医学部皮膚科学講座 助教・講師
2012年  愛媛大学大学院医学系研究科分子機能領域皮膚科学 講師
2018年  愛媛大学大学院医学系研究科分子機能領域皮膚科学 准教授
2021年  愛媛大学大学院医学系研究科分子機能領域皮膚科学 教授(特任)
2023年 特定非営利活動法人領域横断疾患研究機構 理事
2024年 宮崎大学医学部解剖学講座組織細胞化学分野 客員教授
2024年 神奈川歯科大学歯学部病理・組織形態学講座環境病理学 客員教授

専門分野:

皮膚科学, 皮膚自然免疫学, 皮膚病理組織学, 分子機能生理形態学, バイオイメージング

加入学会:

日本皮膚科学会
日本組織細胞化学会 評議員Editorial Board
日本臨床分子形態学会 評議員
IPC Councilor (International Psoriasis Council)
GRAPPA membership (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis)

研究テーマ:

掌蹠膿疱症(膿疱症)及び乾癬の病態生理および治療開発
新規皮膚3次元ライブイメージング方法の開発

主要論文:

Yatsuzuka K, Kawakami R, Niko Y, Tsuda T, Kameda K, Kohri N, Yoshida S, Shiraishi K, Muto J, Mori H, Fujisawa Y, Imamura I, Murakami M. A fluorescence imaging technique suggests that sweat leakage in the epidermis contributes to the pathomechanism of palmoplantar pustulosis. SciRep 2024; 14(1): 378. 【学位論文】

Burden AD, Bissonnette R, Navarini A, Murakami M, Morita A, Haeufel T, Ye B, Baehner F, Terui T. Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis – a Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study. Dermatology and Therapy. 2023; 13(10): 2279–2297.

Yatsuzuka K, Matsumoto T, Sakane Y, Fukaura R, Takeichi T, Akiyama M, Murakami M. The use of certolizumab pegol to successfully treat generalized pustular psoriasis combined with psoriatic uveitis. J Dermatol. 2023; 50(6): e175-e176.

Terui T, Okubo Y, Kobayashi S, Sano S, Morita A, Imafuku S, Tada Y, Abe M, Yaguchi M, Uehara N, Handa T, Tanaka M, Zhang W, Paris M, Murakami M. Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study. Am J Clin Dermatol. 2023; 24(5): 837–847.

Murakami M, Kawakami R, Niko Y, Tsuda T, Imamura T. Research letter: A new fluorescent three-dimensional and deep-imaging technique for histological identification of individual tumor cells in extramammary Paget’ s disease. Exp Dermatol. 2023; 32(5): 712-714.

Yatsuzuka K, Murakami M. A successful switch from guselkumab to tildrakizumab during the treatment of a patient with psoriasis vulgaris. J Cutan Immunol Allergy. 2022; 6: 98-99.

Yatsuzuka K, Murakami M. Comorbidities in Korean patients with palmoplantar pustulosis vs Psoriasis Vulgaris or Pompholyx. JAMA Dermatol. 2022; 158(10): 1220.

Dai X, Murakami M, Shiraishi K, Muto J, Tohyama M, Mori H, Utsunomiya R, Sayama K. EGFR ligands synergistically increase IL-17A-induced expression of psoriasis signature genes in human keratinocytes via IκBζ and Bcl3. Eur J Immunol. 2022; 52(6): 994-1005.

Yatsuzuka K, Murakami M, Kuroo Y, Fukui M, Yoshida S, Muto J, Shiraishi K, Sayama K. Flare-up of generalized pustular psoriasis combined with systemic capillary leak syndrome after coronavirus disease 2019 mRNA vaccination. J Dermatol. 2022; 49(4): 454-458.

Yatsuzuka K, Murakami M. Response to ‘Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)’. Br J Dermatol. 2022; 186(5):908.

Yatsuzuka K, Murakami M, Yoshida S, Utsunomiya R, Watanabe T, Sayama K. Successful treatment of psoriasis vulgaris with apremilast in a patient with decompensated cirrhosis. J Dermatol. 2022; 49(4): e129-e130.

Murakami M, Kawakami R, Niko Y, Tsuda T, Yatsuzuka K, Mori H, Imamura T, Sayama K. New fluorescent three-dimensional and deep-imaging technique confirms a direct relationship between the acrosyringium and vesicles/pustules of palmoplantar pustulosis. J Dermatol Sci. 2021; 102(2): 130-132.

Murakami M, Kawakami R, Niko Y, Tsuda T, Mori H, Yatsuzuka K, Imamura T, Sayama K. High-quality fluorescence imaging of the human acrosyringium using a transparency-enhancing technique and an improved, fluorescent solvatochromic pyrene probe. Acta Histochemica et Cytochemica 2020; 53(6): 131-138.

Murakami M. Guselkumab for the treatment of Palmoplantar pustulosis. Expert Opin Biol Ther. 2020; 12(5): 841-852.

Murakami M and Terui T. Palmoplantar pustulosis: current understanding of disease definition and pathomechanism. J Dermatol Sci. 2020; 98(1): 13-19.

Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, Blauvelt A, Bourcier M, Carvalho A, Cohen A, Foley P, Evans C, Gisondi P, Griffiths C, Hamdy El-Sayed M, Eschevarria C, Finlay A, Kalb R, Leonardi C, Lynde C, Murphy R, Murakami M, Okubo Y, Prens E, Puig L, Seyger M, Skov L, Terui T, Valenzuela F, Ward N, Wu J, Zheng M. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020; 82(1):117-122.

Murakami M, Muto J, Masuda-Kuroki K, Tsuda T, Mori H, Ustunomiya R, Shiraisi K, Sayama K. Pompholyx vesicles contain small clusters of cells with high levels of hyaluronate resembling the pustulovesicles of palmoplantar pustulosis. Br J Dermatol. 2019; 181(6): 1325-1327.

Terui T, Kobayashi S, Okubo Y, Murakami M, Zheng R, Morishima H, Goto R, Kimura T. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: A phase 3, randomized, double-blind, placebo-controlled study. JAMA Dermatol. 2019; 155(10): 1153-1161.

Masuda-Kuroki K, Murakami M, Kishibe M, Kobayashi S, Okubo Y, Yamamoto T, Terui T, Sayama K. Diagnostic histopathological features distinguishing palmoplantar pustulosis from pompholyx. J Dermatol. 2019; 46(5): 399-408.

Masuda-Kuroki, K, Murakami M, Tokunaga N, Kishibe M, Mori H, Utsunomiya R, Tsuda T, Shiraishi K, Tohyama M, Sayama, K. The microbiome of the “sterile” pustules in palmoplantar pustulosis. Exp Dermatol. 2018; 27(12): 1372-1377. 【学位論文】

Terui T, Kobayashi S, Okubo Y, Murakami M, Hirose K, Kubo H. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial. JAMA Dermatol. 2018; 154(3): 309-316.

Mori H, Murakami M, Tsuda T, Kameda K, Utsunomiya R, Masuda K, Shiraishi K, Dai X, Tohyama M, Nakaoka H, Sayama K. Reduced-HMGB1 suppresses poly(I:C)-induced inflammation in keratinocytes. J Dermatol Sci. 2018, 90(2):154-165.

Oda F, Murakami M, Hanakawa Y, Tohyama M, Nakano N, Nishikomori R, Kambe N, Sayama K. A sporadic case of granulomatous disease negative for NOD2 mutations and mimicking Blau syndrome. Clin Exp Dermatol. 2018; 43(1): 57-58.

Murakami M, Kameda K, Tsumoto H, Tsuda T, Masuda K, Utsunomiya R, Mori H, Miura Y, Sayama K. TLN-58, newly discovered hCAP18 processing form, found in the lesion vesicle of palmoplantar pustulosis in the skin. J Invest Dermatol. 2017; 137(2): 322-331.

Namba C, Murakami M, Tohyama M, Sayama K. NB-UVB is an expecting treatment for pityriasis rubra pilaris. Clinical Dermatol. 2016; 4(1): 24-28.

Murakami M, Masuda K, Utsunomiya R, Oda F, Namba C, Sayama K. Cefcapene Pivoxil Hydrochloride Is a Potentially New Treatment for Palmoplantar Pustulosis with Pustulotic Arthro-Osteitis. Dermatology. 2015; 231(4): 304-311.

Masuda K, Murakami M, Ohnishi S, Kukida M, Hanakawa Y, Tohyama M, Sayama K. Case of palmoplantar pustulosis that developed with acute glomerulonephritis. J Dermatol. 2014; 42(1): 111-112.

Murakami M, Kaneko T, Nakatsuji T, Kameda K, Okazaki H, Dai X, Hanakawa Y, Tohyama M, Ishida-Yamamoto A, Sayama K. Vesicular LL-37 Contributes to Inflammation of the Lesional Skin of Palmoplantar Pustulosis. PLoS One. 2014; 9(10): e110677.

Namba C, Murakami M, Hanakawa Y, Tohyama M, Shirakata Y, Tauchi H, Sayama K.  Infantile generalized pustular psoriasis: Successful disease control with intermittent etretinate. J Dermatol. 2014; 41(5): 403-406.

Harder J, Tsuruta D, Murakami M, Kurokawa I. What is the role of antimicrobial peptides (AMP) in acne vulgaris? Exp Dermatol. 2013; 22(6): 386-391.

Murakami M, Ishida-Yamamoto A, Morhenn VB, Koji S. Acute generalised pustular bacterid. Lancet Infect Dis. 2013; 13(8): 655-656.

Kaneko T, Murakami M, Kishibe M, Brattsand M, Morhenn VB, Ishida-Yamamoto A, Iizuka H. Over-Expression of Kallikrein Related Peptidases in Palmoplantar Pustulosis. J Dermatol Sci. 2012; 67(1): 73-76.

Igawa S, Kishibe M, Murakami M, Honma M, Takahashi H, Iizuka H, Ishida-Yamamoto A. Tight Junctions in the Stratum Corneum Explain Spatial Differences in Corneodesmosome Degradation. Exp Dermatol. 2011; 20(1): 53-57.

Murakami M, Hagforsen E, Morhenn VB, Ishida-Yamamoto A, Iizuka H. The patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011; 20(10): 845-847.

Murakami M, Ohtake T, Horibe Y, Ishida-Yamamoto A, Morhenn VB, Gallo RL. Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. J Invest Dermatol. 2010; 130(8): 2010-2016.

Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, Dorschner RA, Bonnart C, Descargues P, Hovnanian A, Morhenn VB, Gallo RL. Elevated serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nature Medicine. 2007; 13(8): 975-980.

Lee PH, Ohtake T, Zaiou M, Murakami M, Rudisill JA, Lin KH, Gallo RL.  Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection. Proc Natl Acad Sci U S A. 2005; 102(10): 3750-3755.

Morhenn VB, Murakami M, O’Grady T, Nordberg J, Gallo RL. Characterization of expression and function of the NMDA receptor in keratinocytes. Exp Dermatol. 2004; 13(8): 505-511.

Murakami M, Lopez-Garcia B, Braff M, Dorschner RA, Gallo RL. Post-secretory processing generates multiple human cathelicidin peptides for enhanced topical antimicrobial defense. J Immunol. 2004; 172(5): 3070-3077.

Hase K, Murakami M, Iimura I, Cole SP, Horibe Y, Ohtake T, Obonyo M, Gallo RL, Eckmann L, Kagnoff MF. Expression of LL-37/hCAP18 by human gastric epithelial cells as a potential host defense mechanism against Helicobactor Pylori. Gastroenterology. 2003; 125(6): 1613-1625.

Dorschner RA, Lin HK, Murakami M, Gallo RL. Neonatal skin in mice and humans expresses increased levels of antimicrobial peptides: Innate immunity during development of the adaptive response. Pedeatrics Research. 2003; 53(4): 566-572.

Gallo RL, Murakami M, Ohtake T, Zaiou M. Biology and clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immun. 2002; 110(6): 823-831.

Murakami M, Ohtake T, Dorshner RA, Gallo RL. Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J Dent Res. 2002; 81(12): 845-850.

Murakami M, Ohtake T, Dorshner RA, Schittek B, Garbe C, Gallo RL. Cathelicidin antimicrobial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol. 2002; 119(5): 1090-1095.